羧甲基化裂褶多糖抗肝癌作用的实验研究

Antihepatocarcinoma effect of CM-SPG

目的:从细胞水平和整体水平探讨羧甲基化裂褶多糖的抗肝癌作用。方法:将两种不同取代度羧甲基化裂褶多糖加入H22小鼠肝癌细胞液中分别培养24、48、72h,用台盼蓝拒染法测试作用后的细胞死亡率;建立小鼠H22肝癌移植性实体瘤模型,将其分为空白对照组、阳性对照组和3种不同取代度羧甲基化裂褶多糖给药组,腹腔注射给药,各组小鼠均连续给药10d后处死并称瘤重,计算抑瘤率。结果:不同取代度、不同时间羧甲基化裂褶多糖作用于H22肝癌细胞的细胞死亡率差异无统计学意义。取代度为0.67和0.93的羧甲基化裂褶多糖,对荷H22肝癌肿瘤小鼠的抑瘤率分别为41.3%和37.9%;取代度为1.14的羧甲基化裂褶多糖则未表现出抑瘤作用。结论:羧甲基化裂褶多糖在细胞水平上对H22小鼠肝癌细胞株无抑制作用;取代度为0.67和0.93的羧甲基化裂褶多糖对小鼠H22肝癌具有一定的抗癌作用,其机制并不是直接抑制癌细胞,而是通过机体因素后间接抑制肿瘤的生长,是一种具有开发潜力的新的候选抗癌药物。

Objective To understand the antibepatocareinoma effect of CM-SPG at cellular and gross levels, Methods （ 1 ）Antihepatocarcinoma effect in vitro： two different concentrations of CM-SPG were added into the suspension of hepatocarcinoma cells from H22 mice. The cells were cultivated for 24, 48 and 72 h, respectively. The cellular mortality was examined by trypan blue dye exclusion. （2）Antihepatocarcinoma effect in vivo： the solid tumor model of mouse H22 hepatocarcinoma was established. The mice were divided into five groups： blank control, positive control and three groups with different concentrations of CM-SPG. CM-SPGs were injected intraperitonealy. The mice in defferent groups were sacrificed after consecutive injection for 10 days. The tumors were weighed to calculate the tumor inhibition rate. Results No statistically significant difference were found in the mortality of hepatocarcinoma cells from H22 mice with different substitution of CM-SPG at different time points. The tumor inhibition rates of H22 mice with hepatocarcinoma were 41.3% and 37.9%, respectively, with 0.67 and 0.93 CM-SPG substitution reaction. The substitution reaction of 1.14 of CM-SPG displayed no significant inhibition efficacy. Conclusions CM-SPG has no significant inhibition function to H22 hepatocarcinoma cell line at cellular level;both 0.67 and 0.93 CM-SPG substitution reactions have certain antitumor effects on H22 hepatocarcinoma mice,whose mechanism is to inhibit the tumor growth indirectly by induction of the host reaction rather than by direct inhibition of tumor cells, So, CM-SPG is a novel, potential drug candidate for antihepatocarcinoma.